TP53 and cancer: Accordingly, a cancer-associated variant was identified in an intron of PSME in all of the cancers linked to NTC/NCC lineage (MEL, GBM, LGG, and MB); PSME is a proteasome activator that promotes MDM2 dependent degradation of p53, preventing apoptosis after DNA damage.